The ALS Therapy Development Institute Partners with Neurotune to investigate Potential Treatments for Motor Neuron Desease. Partnership aimed at Neuromuscular Junction Strength against Disease Course.
The ALS Therapy Development Institute (ALS TDI) announced today that it has entered into collaboration with Neurotune to investigate a potential treatment for ALS (aka Motor Neuron or Lou Gehrig’s desease).
Neurotune launches the world’s first ELISA based diagnostic assay for C-terminal Agrin Fragments (CAF) in blood.
Neurotune AG, a Swiss biopharmaceutical company, announces the launch of its immunoassay, NTCAF ELISA, the world’s first ELISA based assay for sarcopenia.
Neurotune AG is Coordinator of an Eurostars funded Project entitled “Early Diagnosis and Monitoring of Renal Diseases” (Acronym: KIDNEY).
The scope of the project is the validation of a new and most effective diagnostic biomarker (RCAF) for the early monitoring of chronic kidney disease with a possible application in the prognosis of kidney transplant and in acute kidney injury.
Schlieren (Zurich), Switzerland, 14 November 2011. The FDA has granted Neurotune AG an IND for dimiracetam, the company’s lead compound for treatment of neuropathic pain conditions. Neurotune is planning a pivotal study to demonstrate efficacy of dimiracetam in alleviating neuropathic pain in AIDS patients affected with a treatment related symmetrical painful peripheral neuropathy.
Neurotune AG today announced it is leading a consortium of research teams in the DISARCO project, a two-year project focused on developing an immunoassay for the diagnosis of sarcopenia. The consortium has received €720,000 from the European Eurostars Programme to fund the research.
Der BIO-TECHNOPARK® Schlieren-Zürich ist zusammen mit Neurotune, ETH Zürich, Universität Zürich und der Standortförderung des Kantons Zürich Partner im EU-Projekt HealthTIES.